Table 5

 Advantages and disadvantages of statin treatment in the elderly for the secondary prevention of CHD

40–80 years MRC/BHF2070–80 years MRC/BHF2070–82 years PROSPER21
MRC/BHF, Medical Research Council/British Heart Foundation; PROSPER, pravastatin in elderly individuals at risk of vascular disease.
Change in coronary events−27%−20%−19%
Change in stroke events−25%+3%
Development of myopathy0.06%<0.01%
Development of disturbed liver function0.18%<0.01%
Increase in cancer incidenceNo+25%